Clinical data from the Actinium225PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer (WARMTH Act) study, which is a large multicentre cohort involving 488 patients from seven international centres, confirmed that [225Ac]Ac-PSMA RLT is most often used in heavily pre-treated mCRPC patients. The gene discussed is FOLH1; the disease is prostate carcinoma.